
Noemi Lois

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8457565/publications.pdf Version: 2024-02-01



NOFMILOIS

#	Article	IF	CITATIONS
1	Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial. Trials, 2022, 23, 99.	1.6	8
2	Predictive factors associated with anatomical and functional outcomes following panretinal photocoagulation in people with proliferative diabetic retinopathy. Retina, 2022, Publish Ahead of Print, .	1.7	0
3	Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy. Eye, 2022, , .	2.1	1
4	Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy. Ophthalmology, 2021, 128, 561-573.	5.2	15
5	Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort. British Journal of Ophthalmology, 2021, , bjophthalmol-2020-318570.	3.9	3
6	Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study. Health Technology Assessment, 2021, 25, 1-104.	2.8	1
7	Anatomic–Functional Correlates in Lesions of Retinal Vein Occlusion. , 2021, 62, 10.		3
8	Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study. British Journal of Ophthalmology, 2021, , bjophthalmol-2021-318816.	3.9	1
9	Reporting of Complications in Retinal Detachment Surgical Trials. JAMA Ophthalmology, 2021, 139, 898.	2.5	3
10	Reply. Ophthalmology, 2021, 128, e46-e47.	5.2	0
11	The importance of the epithelial fibre cell interface to lens regeneration in an in vivo rat model and in a human bag-in-the-lens (BiL) sample. Experimental Eye Research, 2021, 213, 108808.	2.6	4
12	FIRST FAILED MACULAR HOLE SURGERY OR REOPENING OF A PREVIOUSLY CLOSED HOLE. Retina, 2020, 40, 1-15.	1.7	28
13	IMPACT OF RETINAL ISCHEMIA ON FUNCTIONAL AND ANATOMICAL OUTCOMES AFTER ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN PATIENTS WITH RETINAL VEIN OCCLUSION. Retina, 2020, 40, 1098-1109.	1.7	3
14	Reply. Retina, 2020, 40, e48-e49.	1.7	0
15	Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. The Cochrane Library, 2020, , .	2.8	1
16	A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of Clinical Medicine, 2020, 9, 2225.	2.4	7
17	Targeting QKI-7 in vivo restores endothelial cell function in diabetes. Nature Communications, 2020, 11, 3812.	12.8	39
18	Endothelial Cells Derived From Patients With Diabetic Macular Edema Recapitulate Clinical Evaluations of Anti-VEGF Responsiveness Through the Neuronal Pentraxin 2 Pathway. Diabetes, 2020, 69, 2170-2185.	0.6	9

NOEMI LOIS

#	Article	IF	CITATIONS
19	Risk factors associated with progression to referable retinopathy: a type 2 diabetes mellitus cohort study in the Republic of Ireland. Diabetic Medicine, 2020, 37, 1000-1007.	2.3	7
20	PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA. Retina, 2020, 40, 919-927.	1.7	5
21	Circulating Leukocyte Alterations and the Development/Progression of Diabetic Retinopathy in Type 1 Diabetic Patients - A Pilot Study. Current Eye Research, 2020, 45, 1144-1154.	1.5	19
22	Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. The Cochrane Library, 2020, 12, CD013154.	2.8	7
23	Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy (EMERALD). BMJ Open, 2019, 9, e027795.	1.9	7
24	STAT3 activation in circulating myeloid-derived cells contributes to retinal microvascular dysfunction in diabetes. Journal of Neuroinflammation, 2019, 16, 138.	7.2	22
25	Reply to Correspondence by Calugaru and Calugaru to the Article Entitled "Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion―by Khayat etÂal Survey of Ophthalmology, 2019, 64, 593-594.	4.0	0
26	Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial. Trials, 2019, 20, 122.	1.6	22
27	Fenofibrate for Diabetic Retinopathy. Asia-Pacific Journal of Ophthalmology, 2019, 7, 422-426.	2.5	14
28	Enhanced Function of Induced Pluripotent Stem Cell-Derived Endothelial Cells Through ESM1 Signaling. Stem Cells, 2019, 37, 226-239.	3.2	25
29	lschemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Survey of Ophthalmology, 2018, 63, 816-850.	4.0	73
30	Different lasers and techniques for proliferative diabetic retinopathy. The Cochrane Library, 2018, 2018, 2018, CD012314.	2.8	32
31	Instrumental variable methods for a binary outcome were used to informatively address noncompliance in a randomized trial in surgery. Journal of Clinical Epidemiology, 2018, 96, 126-132.	5.0	6
32	Treatment for diabetic macular oedema: looking further into the evidence. Annals of Eye Science, 2018, 3, 2-2.	2.1	1
33	Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. The Cochrane Library, 2018, , .	2.8	1
34	Polarized retinal pigment epithelium generates electrical signals that diminish with age and regulate retinal pathology. Journal of Cellular and Molecular Medicine, 2018, 22, 5552-5564.	3.6	9
35	Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1411-1418.	1.9	11
36	Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review. Health Technology Assessment, 2018, 22, 1-168.	2.8	43

NOEMI LOIS

#	Article	IF	CITATIONS
37	Diabetic retinopathy and the use of laser photocoagulation: is it cost-effective to treat early?. BMJ Open Ophthalmology, 2017, 2, e000021.	1.6	10
38	The Epidemiology of Stargardt Disease in the United Kingdom. Ophthalmology Retina, 2017, 1, 508-513.	2.4	19
39	Erythropoietin in diabetic retinopathy. Vision Research, 2017, 139, 237-242.	1.4	18
40	Animal Models of Retinal Vein Occlusion. , 2017, 58, 6175.		28
41	The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research, 2016, 51, 156-186.	15.5	730
42	Optical Coherence Tomography for the Monitoring of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 399-406.	5.2	55
43	Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-248.	2.8	53
44	Treatments for macular oedema following central retinal vein occlusion: systematic review. BMJ Open, 2014, 4, e004120.	1.9	21
45	Endothelial Progenitor Cells in Diabetic Retinopathy. Frontiers in Endocrinology, 2014, 5, 44.	3.5	67
46	Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis. BMJ Open, 2014, 4, e005292-e005292.	1.9	26
47	Vitrectomy with Internal Limiting Membrane Peeling versus No Peeling for Idiopathic Full-Thickness Macular Hole. Ophthalmology, 2014, 121, 649-655.	5.2	149
48	Fundus autofluorescence in patients with retinal pigment epithelial (RPE) tears: an in-vivo evaluation of RPE resurfacing. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1059-1063.	1.9	19
49	Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-254.	2.8	17
50	A Longitudinal Study of Stargardt Disease: Clinical and Electrophysiologic Assessment, Progression, and Genotype Correlations. American Journal of Ophthalmology, 2013, 155, 1075-1088.e13.	3.3	121
51	RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2013, 33, 13-22.	1.7	76
52	Reply. Retina, 2013, 33, 1998-1999.	1.7	0
53	Cost-effectiveness of internal limiting membrane peeling versus no peeling for patients with an idiopathic full-thickness macular hole: results from a randomised controlled trial. British Journal of Ophthalmology, 2012, 96, 438-443.	3.9	24
54	Progression of Retinal Pigment Epithelial Atrophy in Stargardt Disease. American Journal of Ophthalmology, 2012, 154, 146-154.	3.3	82

NOEMI LOIS

#	Article	IF	CITATIONS
55	GEOGRAPHIC ATROPHY IN RETINAL ANGIOMATOUS PROLIFERATION. Retina, 2011, 31, 1043-1052.	1.7	73
56	Internal Limiting Membrane Peeling versus No Peeling for Idiopathic Full-Thickness Macular Hole: A Pragmatic Randomized Controlled Trial. , 2011, 52, 1586.		220
57	Progression of Electroretinogram Responses in Stargardtâ€Fundus Flavimaculatus: A longitudinal study. Acta Ophthalmologica, 2011, 89, 0-0.	1.1	1
58	Electric currents and lens regeneration in the rat. Experimental Eye Research, 2010, 90, 316-323.	2.6	21
59	Electrical estimulation of retinal pigment epithelial cells. Experimental Eye Research, 2010, 91, 195-204.	2.6	20
60	Clinical and cost-effectiveness of internal limiting membrane peeling for patients with idiopathic full thickness macular hole. Protocol for a Randomised Controlled Trial: FILMS (Full-thickness macular) Tj ETQq0 0 0	rg₿ITdOve	rlo ale 10 Tf 50
61	Internal Limiting Membrane Peeling in Vitreo-retinal Surgery. Survey of Ophthalmology, 2008, 53, 368-396.	4.0	94
62	Environmental tobacco smoke exposure and eye disease. British Journal of Ophthalmology, 2008, 92, 1304-1310.	3.9	85
63	Effect of short-term macrophage depletion in the development of posterior capsule opacification in rodents. British Journal of Ophthalmology, 2008, 92, 1528-1533.	3.9	9
64	Posterior Capsule Opacification in Mice. JAMA Ophthalmology, 2005, 123, 71.	2.4	28
65	Effect of TGF-β2 and Anti–TGF-β2 Antibody in a New In Vivo Rodent Model of Posterior Capsule Opacification. , 2005, 46, 4260.		24
66	Fundus autofluorescence in stargardt macular dystrophy–fundus flavimaculatus. American Journal of Ophthalmology, 2004, 138, 55-63.	3.3	167
67	Pseudophakic retinal detachment. Survey of Ophthalmology, 2003, 48, 467-487.	4.0	173
68	A New Model of Posterior Capsule Opacification in Rodents. , 2003, 44, 3450.		51
69	Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss11Commercial interests: None American Journal of Ophthalmology, 2002, 133, 341-349.	3.3	179
70	Phenotypic Subtypes of Stargardt Macular Dystrophy–Fundus Flavimaculatus. JAMA Ophthalmology, 2001, 119, 359.	2.4	278
71	Intrafamilial variation of phenotype in Stargardt macular dystrophy-Fundus flavimaculatus. Investigative Ophthalmology and Visual Science, 1999, 40, 2668-75.	3.3	58
72	Fenofibrate for diabetic retinopathy. The Cochrane Library, 0, , .	2.8	4